Get the Stockscreener App
1.575
1.56%
-0.025
Nautilus Biotechnology Inc stock is traded at $1.575, with a volume of 16,144.
It is down -1.56% in the last 24 hours and down -22.79% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
See More
Previous Close:
$1.60
Open:
$1.63
24h Volume:
16,144
Relative Volume:
0.13
Market Cap:
$200.90M
Revenue:
-
Net Income/Loss:
$-63.68M
P/E Ratio:
-3.0288
EPS:
-0.52
Net Cash Flow:
$-54.15M
1W Performance:
-7.89%
1M Performance:
-22.79%
6M Performance:
-35.19%
1Y Performance:
-43.14%
1-Day Range:
$1.57
$1.65
1-Week Range:
$1.57
$1.75
52-Week Range:
$1.5598
$3.09
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
1.57 | 200.90M | 0 | -63.68M | -54.15M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.55 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.47 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.71 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.07 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
117.11 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
View All
Nautilus Biotechnology Inc Stock (NAUT) Latest News
Nautilus Biotechnology (NAUT) Projected to Post Quarterly Earnings on Thursday - Defense World
Blade Air Mobility Leads The Charge Among 3 US Penny Stocks - Simply Wall St
Nautilus Biotechnology to Participate in the TD Cowen 45th Annual Healthcare Conference - The Manila Times
Exclusive: Nautilus Biotech Unveils Next-Gen Protein Analysis Breakthrough at Major Healthcare Summit - StockTitan
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Down 68.8% in January - MarketBeat
Nautilus Biotechnology (NASDAQ:NAUT) Stock Price Down 5.9%Time to Sell? - MarketBeat
SG Americas Securities LLC Buys 9,904 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Nautilus Bio Q4 Earnings Alert: Protein Analysis Pioneer Reports Feb 27 - StockTitan
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - GlobeNewswire
One Nautilus Biotechnology Insider Raised Their Stake In The Previous Year - Yahoo Canada Finance
Nautilus Biotech announces board member changes By Investing.com - Investing.com Australia
Nautilus Biotech announces board member changes - MSN
Nautilus Biotechnology Announces Board Member Departures - MSN
NAUTILUS BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Barclays PLC Buys 47,059 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Jeff Bezos Stock Portfolio: Top Investment Picks - CoinCodex
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Down 14.2% in December - MarketBeat
Barclays PLC Has $1.04 Million Holdings in Northfield Bancorp, Inc. (Staten Island, NY) (NASDAQ:NFBK) - Defense World
Jane Street Group LLC Sells 25,020 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
EZCORP, Inc. (NASDAQ:EZPW) Shares Acquired by Barclays PLC - Defense World
US Penny Stocks To Watch In January 2025 - Simply Wall St
Dermata Therapeutics Inc (DRMA): Major Improvements, Worth A Look - Stocks Register
Barclays PLC Has $303,000 Stock Holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
State Street Corp Lowers Holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
The Manufacturers Life Insurance Company Invests $67,000 in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
US Penny Stocks Spotlight: Information Services Group Among 3 Top Picks - Simply Wall St
With 32% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot riding on the company's future - Yahoo Finance
Nautilus Biotechnology (NASDAQ:NAUT) Cut to “Sell” at The Goldman Sachs Group - Defense World
Goldman Sachs Downgrades Nautilus Biotechnology (NAUT) - MSN
Goldman Sachs cuts Nautilus Biotechnology stock to sell By Investing.com - Investing.com Canada
Goldman Sachs cuts Nautilus Biotechnology stock to sell - Investing.com
Nautilus Biotechnology Inc (NAUT-Q) QuotePress Release - The Globe and Mail
Nautilus Biotechnology Reports Q3 2024 Financial Results - MSN
Nautilus Biotechnology (NASDAQ:NAUT) Stock Price Up 0.8% – Here’s What Happened - Defense World
Nautilus Biotechnology (NASDAQ:NAUT) Shares Up 0.8%What's Next? - MarketBeat
3 US Penny Stocks With Market Caps Up To $400M - Simply Wall St
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award - BioSpace
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research's Distinguished Investigator Award - Quantisnow
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2024 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology Co-founder and Chief Scientist Parag - GlobeNewswire
Nautilus Biotechnology Faces ESG Challenges Amid Regulatory Pressure and Investor Scrutiny - TipRanks
Glass House Brands to Host Third Quarter 2024 Conference Call on November 13, 2024 - The Manila Times
Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference - GlobeNewswire
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.12%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):